KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

Ítems similars

• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
  per: Pao, William, et al.
  Publicat: (2005)
• Morphologic Features of Adenocarcinoma of the Lung Predictive of Response to the Epidermal Growth Factor Receptor Kinase Inhibitors Erlotinib and Gefitinib
  per: Zakowski, Maureen F., et al.
  Publicat: (2009)
• EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
  per: Pao, William, et al.
  Publicat: (2004)
• Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor epidermal growth factor receptor (EGFR) mutations
  per: Janjigian, Yelena Y., et al.
  Publicat: (2011)
• Association of KRAS and EGFR Mutations with Survival in Patients with Advanced Lung Adenocarcinomas
  per: Johnson, Melissa L., et al.
  Publicat: (2012)